Avant Immunotherapeutics’s Oral Combined Enterotoxigenic E. coli-Cholera Vaccine to Enter Phase 1 Safety Study Funded by the National Institutes of Health (NIH)

NEEDHAM, Mass.--(BUSINESS WIRE)--AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) today announced an agreement with the Division of Microbiology and Infectious Diseases of the National Institute of Allergy and Infectious Diseases (NIAID), an institute of the National Institutes of Health (NIH), whereby NIAID will sponsor a Phase 1 study of AVANT’s investigational single-dose, oral vaccine designed to offer combined protection against both enterotoxigenic Escherichia coli (ETEC) and cholera.